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Abstract
Breast cancer is a leading cancer diagnosis among premenopausal women around the world. 
Unlike rates in postmenopausal women, incidence rates of advanced breast cancer have increased 
in recent decades for premenopausal women. Progress in identifying contributors to breast cancer 
risk among premenopausal women has been constrained by the limited numbers of premenopausal 
breast cancer cases in individual studies and resulting low statistical power to subcategorize 
exposures or to study specific subtypes. The Premenopausal Breast Cancer Collaborative Group 
was established to facilitate cohort-based analyses of risk factors for premenopausal breast cancer 
by pooling individual-level data from studies participating in the United States National Cancer 
Institute Cohort Consortium. This paper describes the Group, including the rationale for its initial 
aims related to pregnancy, obesity, and physical activity. We also describe the 20 cohort studies 
with data submitted to the Group by June 2016. The infrastructure developed for this work can be 
leveraged to support additional investigations.
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Introduction
Breast cancer is the most common cancer diagnosed among women worldwide, with an 
estimated 1.67 million cases diagnosed in 2012, accounting for a quarter of all new cancers 
in women. Breast cancer is also the most common cancer diagnosed among women aged 
15–39 years worldwide (1). Further, breast cancer among premenopausal women often 
presents at more advanced stages (2) and, at the youngest ages, has less favorable prognosis 
(3) than among postmenopausal women.
Identifying contributors to breast cancer risk in younger women is critical to prevention. In 
the United States, incidence rates of advanced breast cancer have increased among 
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premenopausal women in recent decades, whereas they have consistently decreased among 
women 60 and older during the same period (4). Accumulating evidence supports etiologic 
heterogeneity between pre- and postmenopausal breast cancer. Several lifestyle factors, 
including childbirth (5), obesity (6), and cigarette smoking (7) have been reported to have 
differential associations with breast cancer risk before and after menopause. Breast cancer 
subtypes, including those defined by gene expression (8), or clinical markers including 
estrogen receptor (ER), progesterone receptor (PR), or HER2/neu oncogene expression, have 
emerged as critical considerations for risk factor associations and are differentially 
distributed by menopausal status (9). Investigations of breast cancer etiologic heterogeneity 
require large sample sizes to have sufficient statistical power to account jointly for 
menopausal status and tumor subtype.
The Premenopausal Breast Cancer Collaborative Group (the Collaborative Group) was 
established to facilitate cohort-based analyses of risk factors for premenopausal breast 
cancer, both overall and according to tumor characteristics. This paper describes the 
formation of the Collaborative Group, the methods used for ongoing efforts, and provides 
the rationale for initial analyses related to pregnancy, obesity, and physical activity. The 
infrastructure developed to address these questions can support future investigations of 
additional potential risk factors.
Collaborative Group Studies
The National Cancer Institute (NCI) Cohort Consortium was formed to address the need for 
large-scale collaborations to pool data in cohort studies of cancer and hence to quicken the 
pace of research (http://epi.grants.cancer.gov/Consortia/cohort.html). The Collaborative 
Group was initiated within the Cohort Consortium in 2013 by investigators at The Institute 
of Cancer Research (ICR) in London and the National Institute of Environmental Health 
Sciences (NIEHS). The ICR and the NIEHS serve as the Data Coordinating Centers.
Eligibility
Prospective cohorts in the Cohort Consortium with at least 100 female breast cancers 
diagnosed during follow-up before age 55 and data collection at 2 or more time points 
(baseline and at least one follow-up, to allow for exposure information and menopausal 
status to be updated) are eligible to participate.
Participating cohorts
This report describes the 20 cohort studies (counting the European Prospective Investigation 
into Cancer and Nutrition, which has many cohorts within it, as a single cohort)(6, 10–28) 
with data submitted to the Collaborative Group as of June 2016. Participating cohorts are 
shown in Table 1 and span North America, Europe, Asia, and Australia. The numbers of 
female participants from these cohorts aged <55 at enrollment ranges from 5,671 (Campaign 
against Cancer and Heart Disease) to 117,733 (Nurses’ Health Study cohort). The cohorts 
were initiated as early as 1950 (the Radiation Effects Research Foundation Life Span Study) 
or as recently as 2003 (Generations and Sister Study cohorts). All cohorts have conducted 
more than one round of data collection; however, follow-up data are not yet fully available 
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for three cohorts. The number of follow-up rounds for which data have been submitted as of 
June 1, 2016 ranged from 1 to 16 across cohorts.
Breast cancer ascertainment
To date, data have been received for 1,030,761 women, and include 21,766 incident invasive 
or in situ breast cancers diagnosed after study enrollment and before age 55 years (Table 2). 
Across studies, cancer diagnoses are identified by linkage with city/state/provincial/regional 
(10, 12, 13, 23, 28–31) or national (11, 12, 14, 24, 26, 32, 33) population-based cancer 
registries, and/or through self-report followed by medical record review (6, 10, 11, 14, 15, 
25, 34, 35). All participating studies established case ascertainment procedures and 
published findings related to incident breast cancer risk prior to joining the Collaborative 
Group.
Data exchange and harmonization
After approval by the NCI Cohort Consortium executive committee, the aims of the 
proposed collaboration were circulated to all Consortium members in 2013. Key exposure, 
covariate, and outcome information necessary to address the initial analyses and potential 
confounding or effect modification was identified by the Coordinating Centers. Complete 
capture of all information across exposures is not required for participation.
After confirming eligibility, a data request template is sent to cohorts that wish to participate. 
Requested exposure data include: age/year of cohort entry, length of follow-up, demographic 
characteristics (age, race/ethnicity, education, socioeconomic status), lifestyle factors 
(physical activity, anthropometric characteristics, alcohol intake, smoking information, 
mammography use), reproductive history (menarche, menstrual cycle characteristics, 
gravidity, parity, pregnancy complications, infertility, breastfeeding, hormonal medications, 
menopausal status), benign breast disease, and family history of breast cancer (Supplemental 
Table 1). Most characteristics are requested at enrollment and each follow-up, as available. 
Breast cancer information includes age at diagnosis, stage, grade, histology, and expression 
of ER, PR, HER2, CK5/6, or EGFR. Participating studies are asked where possible to recode 
their own data to fit the data request template to minimize the potential for error in the 
recoding or understanding of variables in their original form. However, if this isnot possible 
due to programming support constraints or other reasons, data are sent to the Coordinating 
Centers in their original form with a study-specific contact person identified to address 
questions from Coordinating Center programmers who reformat the information to fit the 
standard definitions in the data request template.
After data transfer agreements are signed between each individual study and the 
Coordinating Centers, completed datasets were transferred to the coordinating centers using 
secure file transfer protocols. Each cohort submits their data to one of the two Coordinating 
Centers who are responsible for data transfer and harmonization procedures. By having two 
data coordinating sites, one located in the United States and the other in the United 
Kingdom, we are able to minimize time zone differences to facilitate rapid communication, 
and accommodate studies that are only able to send data to certain locations because of 
country-specific information governance requirements.
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Data harmonization procedures are standardized across Coordinating Centers. Quality 
control checks are run on each dataset to identify (i) potential data inconsistencies for each 
questionnaire round (e.g. nulliparous women reporting more than zero births), (ii) 
inconsistencies between questionnaire rounds (e.g. number of births at follow-up being 
lower than at baseline questionnaire), and (iii) implausible values. Data checking procedures 
are automated with a shared program that was run at each Coordinating Center with 
standardized output. Each cohort is contacted regarding any issues that were identified, and 
clarifications or updates are incorporated into the study-specific dataset. Where issues could 
not be resolved, pre-established recoding rules are applied to the data. When study-specific 
variables can not be recoded to meet the data template formats (e.g. age at exposure was 
collected in categories but a continuous variable was requested), differences are documented 
and original data are retained for potential future use. Once the datasets are recoded to the 
standardized formats, data are merged to create a pooled dataset containing values from all 
cohorts.
Defining menopausal status
A primary issue for the Collaborative Group analyses is the definition of menopausal status 
during follow-up and at diagnosis. Menopausal status was ascertained by cohorts at each 
follow-up round for which it was available. In addition, we request at least one follow-up 
round after age 55 or breast cancer diagnosis (if available) to allow menopausal status to be 
defined retrospectively. In analyses conducted by menopausal status we will explore 
different lag periods to determine patterns for ‘premenopausal’ or ‘perimenopausal’ breast 
cancer, as menopause can be a gradual transition.
Statistical approach
Two statistical approaches are being used to analyze the data. We first examine study-
specific estimates and a pooled estimate across studies using a random-effects model that 
weights estimates by the inverse of the study-specific variance (36–38). An advantage of this 
approach is that each study-specific estimate can be derived based on its own available 
covariates. Cochran’s Q statistic is used to examine statistical heterogeneity between studies 
by comparing a weighted measure of difference between individual study estimates and the 
pooled estimate (39, 40). We calculate the I2 statistic to examine the proportion of variance 
that is due to between-study heterogeneity rather than chance (41). Potential sources of 
heterogeneity are investigated.
Maximum flexibility for confounder adjustment and assessment of effect modification can 
be achieved by pooling individual-level data across cohorts. If homogeneity assumptions are 
not violated, we pool data into a single dataset to conduct aggregate analyses stratified by 
study and adjusted for potential confounders that are available in all included studies.
In both approaches, Cox regression models are used to calculate hazard ratios (HR) and 95% 
confidence intervals (CI) for breast cancer (42). Regression models are constructed with age 
as the time scale such that person-time is accrued from age at cohort entry until breast 
cancer diagnosis, age at last follow-up, or other exit age, whichever occurred first. Follow-up 
time is stratified by time-updated exposures obtained from follow-up questionnaires, as 
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appropriate. We test the proportional hazards assumption for exposures of interest, and in 
case of time-varying associations, e.g. an interaction between attained age and the risk factor 
of interest, we investigate the addition of time-varying covariates in the model. In pooled 
analyses, potential variation in the association between exposures and breast cancer risk 
according to tumor subtype are assessed using Cox proportional hazards regression 
accounting for alternative tumor subtypes as competing risks (43, 44).
Rationale for initial aims
Pregnancy
A “dual effect” of pregnancy on breast cancer risk has been used to describe the short-term 
increase in breast cancer risk observed after childbirth followed by a long-term protective 
effect of parity. This pattern has been reported in epidemiological studies nested within 
European population registries (45–49) and in other case-control (50–55) and cohort (56) 
studies. Observational studies have reported 1.25 to 3-fold increases in breast cancer risk for 
up to 10 years after the last birth (5, 57). The magnitude of the pregnancy-related increase in 
breast cancer risk varies across studies, and may be influenced by maternal, pregnancy, or 
post-partum characteristics. Although a period of increased breast cancer risk after childbirth 
has been reported across several studies, it remains unclear whether this observation is 
different for, or limited to, specific groups defined by age (5, 50, 51), parity (45, 52, 53), oral 
contraceptive use (58), breastfeeding practices, family history of breast cancer (48, 59), or 
varies by breast cancer subtype (55, 56, 60) or other tumor characteristics (61, 62).
Women who have a first birth at an older age may have the greatest initial increase in breast 
cancer risk, and the longest interval until a protective effect appears (5, 49, 54, 63). Over the 
last 50 years, more women have postponed childbirth to older ages (5); this trend may have 
contributed to the increasing advanced-stage breast cancer rates among reproductive-age 
women. Pregnancy may also have opposite effects on risks of different breast cancer 
subtypes. For example, without considering menopausal status or subtype, parity reduces 
overall breast cancer risk by ~30% (64). However, parous women have a 50–90% increased 
risk of basal-like or ER-/PR- breast cancer overall (56, 65, 66). Associations for pre- and 
postmenopausal breast cancer combined often reflect patterns among the majority 
postmenopausal breast cancer cases. Our study will be well positioned to examine potential 
variation in the association between recent pregnancy and breast cancer subtype among 
premenopausal women. Others have proposed that pregnancy-related increases in breast 
cancer risk may also be affected by the relatively greater influence of genetic predisposition 
at younger versus older ages at diagnosis (48). In support of this hypothesis, at least two 
studies have shown stronger associations with recent birth and breast cancer risk among 
women with a mother or sister who was diagnosed with breast cancer (48, 59).
Theories to explain the transient increased risk of breast cancer after childbirth vary. High 
levels of estrogen and progesterone and the rapid expansion of breast cells during pregnancy 
could promote latent initiated tumor cells. However, breast tumors diagnosed postpartum are 
more often at an advanced stage and are associated with lower survival compared with those 
diagnosed during pregnancy (67–69). This evidence has led to increased focus on the role of 
post-partum exposures, including lactational involution (the process that returns the 
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mammary gland to a non-milk producing state), as contributors to a pro-tumorigenic 
microenvironment that may be favorable for cancer cell migration and metastasis (70). 
Potential adverse effects of lactational involution on the breast microenvironment must also 
be reconciled with demonstrated lower risks of specific tumor subtypes among parous 
women who breastfeed, including ER-negative or basal-like tumors that confer a worse 
prognosis (56, 65). A better understanding of the factors that contribute to short-term 
increases in breast cancer risk after pregnancy, including potential variation by age, parity, 
oral contraceptive use, breastfeeding, family history, or tumor subtype could provide 
necessary information for refining hypotheses about carcinogenesis in reproductive-age 
women (71). Individual studies have had insufficient statistical power or have lacked key 
information to evaluate these characteristics jointly, making the Collaborative Group an ideal 
setting in which to advance understanding of pregnancy’s role in premenopausal breast 
cancer development.
BMI and other anthropometrics
There is epidemiological evidence for higher BMI at premenopausal ages having an inverse 
association with breast cancer risk (72–75). Higher adiposity in childhood and adolescence 
appears to be associated with a lower risk of breast cancer at both premenopausal (73, 76–
78) and postmenopausal (77–79) ages. Whether further weight gain contributes to additional 
reductions in premenopausal breast cancer risk is not entirely clear (80, 81). A protective 
effect of adiposity at premenopausal ages is in contrast to the effect of adiposity at 
postmenopausal ages, with greater BMI after menopause associated with higher risk of 
breast cancer, probably through production of estrogens by aromatase in adipose tissue (82).
The reason for the protective effect of adiposity at premenopausal ages is unclear, although 
several hypotheses have been put forward. Fewer ovulatory cycles in heavier women, and 
consequent lower sex hormone levels, has been suggested as a potential explanation (83). 
Similarly, an effect of polycystic ovary syndrome (PCOS) has been proposed, although 
Nurses’ Health Study II data did not support this (73). To find the reasons for the inverse 
associations with premenopausal adiposity, large study populations are needed to produce 
stable estimates and to stratify by potentially explanatory factors.
Few published studies have had sufficiently large numbers of premenopausal cases to 
produce age-specific estimates over a range of ages, or to explore whether risks differ by 
other explanatory factors or by breast cancer subtype. The few that stratified by established 
breast cancer risk factors such as parity have so far reported risk estimates to be similar 
across these factors (72, 78). The association between adiposity and premenopausal breast 
cancer has been reported to vary by ethnicity, with strong associations in Caucasian, but not 
in Asian (84) or African-American (85), women, and associations are possibly stronger for 
ER+ than ER- premenopausal breast cancer (73). It is not clear what level of BMI confers 
the highest breast cancer risks – one study reported a non-linear association between BMI 
and risk, with the highest risk around 24 kg/m2 (72).
The Collaborative Group, with its large number of cases in the pooled dataset and data on a 
wide range of risk factors, will be able to clarify the contribution of premenopausal adiposity 
to breast cancer risk, by examining which subtypes of breast cancer are affected, analyzing 
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associations by exposures such as menstrual factors, and by assessing the effect of changes 
in adiposity over time.
Physical activity
Physical activity is of particular interest in that it constitutes a potentially modifiable risk 
factor for breast and other cancers. For premenopausal women, the effect of physical activity 
on reducing breast cancer risk appears to be smaller and less certain than for 
postmenopausal women (86). However, very few studies (35, 87, 88) have published 
prospective data for premenopausal breast cancer risk in relation to physical activity, 
whereas others have published by age at breast cancer (89–91) or menopausal status at study 
entry (92–95), or have included premenopausal women in their study but did not publish 
effect estimates for these women separately (96, 97).
The biological mechanisms through which physical activity could exert an effect in 
premenopausal women is less clear than in postmenopausal women, but might be through an 
effect on menarche, menstrual dysfunction, cycle length, endogenous hormone levels or 
estrogen metabolism (98–100). A smaller effect of physical activity in premenopausal than 
postmenopausal women is possible because, in contrast to postmenopausal women, in whom 
the protective effect of physical activity on breast cancer risk is partly through its effect on 
reducing adiposity, adiposity in premenopausal women has a protective effect on breast 
cancer risk. Additionally, the impact of physical activity on hormone levels might be less 
influential among premenopausal women given their high levels of circulating hormones.
To aid prevention, information is needed on the type, frequency and intensity of exercise 
required to influence breast cancer risk, as well as the ages and characteristics of women for 
whom it is most effective. There might be periods of life during which physical activity has 
a higher impact than others, such as the time period between menarche and first birth (101). 
There is also emerging evidence of differential effects of activity by ethnicity, weight, parity 
and family history of breast cancer, but mostly based on data from postmenopausal women 
(35, 91, 102). It is a limitation, however, that physical activity information is collected in 
many different ways and is difficult to harmonize (103).
The Collaborative Group aims to address premenopausal breast cancer risk by frequency, 
intensity, type and ages of exercise, within strata defined by factors such as BMI, family 
history of breast cancer and age at diagnosis, and to explore specific breast cancer subtypes 
and stages, on a much larger scale than previously. The information gained can be used to 
advise young women about the extent and type of exercise that can influence their breast 
cancer risk.
Opportunities and challenges
The Collaborative Group is an international collaboration formed to address etiological 
factors for breast cancer that may be particular to, or differ in, premenopausal or 
perimenopausal women. By harmonizing a wide range of exposure variables across 20 
studies and developing quality assurance and analysis programs, our collaboration is in a 
position to conduct initial analyses of pregnancy, obesity and physical activity, and to 
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leverage the research infrastructure and established collaboration model for investigations of 
other risk factors. Our initial aims do not require the use of biospecimens. However, 
biospecimens have been collected in many of the participating studies, as described in the 
Cancer Epidemiology Descriptive Cohort Database (available at https://cedcd.nci.nih.gov/
biospecimen.aspx) and could potentially be incorporated to address future hypotheses.
Some limitations and challenges have emerged. As in many consortia, information from the 
participating studies in the Collaborative Group was not collected with future pooling efforts 
in mind and follow-up data are not collected at standardized intervals. Therefore, 
harmonization efforts must identify common data elements that are collected with minimal 
levels of measurement error. Identification of these elements can be complicated by 
questionnaires and codebooks that must be translated to a common language.
Another aspect of working on pooling cohorts that requires planning and forethought is the 
potential for overlap of participants between studies, for example, in Scandinavian countries 
with multiple cohorts that have wide geographic catchment areas. Although the existence of 
national identifiers makes it theoretically possible to identify women who may contribute 
information to more than one study in a country, the logistics for obtaining approval and 
merging datasets can be prohibitive. Therefore, we have worked with study investigators to 
identify the individual cohorts within a country with the most relevant information for 
specific Collaborative Group aims, and to develop strategies for excluding specific 
geographic regions from one cohort, but not another, where overlap of cohort catchment 
areas is known to exist.
The value of cancer consortia to address scientific questions efficiently and create new 
opportunities has become increasingly recognized (104). Conducting analyses across 
multiple studies requires ongoing communication and transparency. Our Collaborative 
Group holds in-person working group meetings in conjunction with the NCI Cohort 
Consortium annual meeting, as well as regular telephone conferences. These meetings 
provide a forum to discuss additional hypotheses that can be addressed in the future to 
maximize the value of the created infrastructure. The Cohort Consortium provides valuable 
coordinating and communication services and dedicated time and space through the annual 
meeting; however, other research support for data preparation, ongoing infrastructure 
development, and dedicated time for collaboration remains a challenge faced across many 
large-scale projects. Our Collaborative Group and others continue to work to identify and 
streamline data sharing models to maximize productivity and collaborative opportunity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Breast cancer characteristics among women younger than 55 years across
Characteristic Combined N Total N studies with data available*
Total breast cancers diagnosed 21,766 20 (all)
Age at diagnosis (years) 20 (all)
 <30 32
 30–39 1,245
 40–44 3,340
 45–49 7,053
 50–54 10,096
Extent of disease 20
 In situ 3,651
 Invasive 17,357
 Missing 758
Estrogen receptor status 16
 Positive 9,583
 Negative 3,182
 Borderline 52
 Missing 8,949
Progesterone receptor status 16
 Positive 7,919
 Negative 3,939
 Borderline 95
 Missing 9,813
HER2/neu overexpression 11
 Positive 1,093
 Negative 4,808
 Borderline 29
 Missing 15,836
*
contributed as of June 2016.
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